On October 2, HANSOH PHARMA fell 3.97% in regular trading, trading at 33.9 HKD/share, with turnover of HKD 359 million. The decline reflects lingering pressure from the European Commission's September 25 decision to revoke the EU marketing authorization for Aumolertinib (marketed as Aumseqa overseas), compounded by broad-based weakness across the pharmaceutical sector.

The revocation stemmed from a procedural issue: AstraZeneca filed a lawsuit alleging that Hansoh's marketing application referenced clinical data for Tagrisso that were within their EU data protection period at the time of the submission. The EU Commission initiated revocation proceedings before the court case was resolved. Hansoh has emphasized the decision is unrelated to the drug's quality, safety, or efficacy, and plans to resubmit a marketing application to the EMA based on its original data package. Aumolertinib has not yet generated overseas sales revenue, and the UK marketing authorization remains valid.

Sector headwinds added further pressure, with major peers all declining: CSPC PHARMA down 2.09%, HENGRUI PHARMA down 2.87%, SIMCERE PHARMA down 3.29%, and ASYMCHEM down 4.11%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)